People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results